Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Gastroenterología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study
INTERVENTIONAL
Inicio: 1 de abr de 2005
ID: NCT00232258
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 1 de oct de 2025
ID: NCT07196748
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
INTERVENTIONAL
Inicio: 28 de dic de 2023
ID: NCT05934526
Terminado
Fase 2
ClinicalTrials.gov
Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00550004
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
INTERVENTIONAL
Inicio: 1 de dic de 2023
ID: NCT06215716
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
INTERVENTIONAL
Inicio: 23 de oct de 2025
ID: NCT07076121
Terminado
Fase 3
ClinicalTrials.gov
Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00678587
Terminado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).
INTERVENTIONAL
Inicio: 1 de feb de 2008
ID: NCT00577148
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
INTERVENTIONAL
Inicio: 20 de jul de 2009
ID: NCT00908752
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 7 de mar de 2018
ID: NCT03398148
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
INTERVENTIONAL
Inicio: 12 de oct de 2016
ID: NCT02872116
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
INTERVENTIONAL
Inicio: 18 de dic de 2017
ID: NCT03104413
Completado
Fase 3
ClinicalTrials.gov
Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.
INTERVENTIONAL
Inicio: 1 de jun de 2006
ID: NCT00332566
Terminado
Fase 2
ClinicalTrials.gov
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
INTERVENTIONAL
Inicio: 1 de sept de 2009
ID: NCT00958841
Completado
Fase 4
ClinicalTrials.gov
A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081
INTERVENTIONAL
Inicio: 5 de sept de 2013
ID: NCT01618305
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 13 de sept de 2022
ID: NCT05528510
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
INTERVENTIONAL
Inicio: 18 de abr de 2024
ID: NCT06319820
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
INTERVENTIONAL
Inicio: 4 de feb de 2021
ID: NCT04567615
Completado
ClinicalTrials.gov
Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America
OBSERVATIONAL
Inicio: 11 de ago de 2023
ID: NCT05924789
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 6 de dic de 2018
ID: NCT03653026
Anterior
1
...
16
17
18
...
434
Siguiente
Filtros